TCTR20210720005
Recruiting
Phase 2
Preliminary study: Safety and Immunological Response following COVID-19 Vaccination in COVID-19 survivors
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19 survivors
- Sponsor
- Faculty of Medicine Siriraj Hospital
- Enrollment
- 180
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Males or females at least 18 years of age (inclusive)
- •2\. Had a history of SARS\-CoV\-2\-positive by RT\-PCR from airway specimens at screening day (10\+/\-4 weeks or 20\+/\-4 weeks after detection)
- •3\. Can understand Thai language through speaking, reading and writing
- •4\. Able to communicate through electronic tools such as Google form or line
- •5\. Capable of attending all study visits according to the study schedule
- •6\. Capable of informed consent and provision of written informed consent before any study procedures
Exclusion Criteria
- •1\. Have history of severe drug or vaccine allergy (anaphylaxis)
- •2\. Have received blood transfusion, plasma, blood product, blood components, immunoglobulins, antiviral or antibodies within the last 90 days
- •3\. Have history of cigarettes smoking, alcohol drinking and history of drug abuse
- •4\. Be pregnant
- •5\. Have history of any vaccination within 14 days before screening visit
- •6\. Had received more than one COVID\-19 vaccination before diagnosis of COVID\-19 infection
- •7\.Had received any COVID\-19 vaccination after Yes
- •diagnosis of COVID\-19 infection
- •8\. Have unstable disease or could not control the symptom
- •9\.Have history of immunodeficiency or use immunosuppressant or steroid drugs?
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccination in The Booster (3rd dose)healthy volunteerSafety and Immunological Response Intradermal COVID-19 vaccinationTCTR20210907003Faculty of Medicine Siriraj Hospital, Mahidol University60
Not yet recruiting
Phase 1
A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccination with Accelerate RegimeHealthy volunteerCOVID-19vaccinesafetyimmunological responseintradermalAccelerate RegimenTCTR20210904004Health Systems Research Institute (HSRI)60
Not yet recruiting
Phase 1
A Pilot Study: Safety and Immunological Response following Intradermal COVID-19 vaccinatiohealthy volunteerSafety and Immunological ResponseIntradermalCOVID-19 vaccinationTCTR20210903006Faculty of Medicine Siriraj Hospital, Mahidol University80
Completed
Phase 1
Safety and immunogenicity of ACT-1239 in healthy volunteersMalariaInfection - Other infectious diseasesACTRN12619001022156Artificial Cell Technologies, Inc.50
Active, not recruiting
Phase 1
A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria - AMA1-C1/CPG Blood Stage ChallangeEUCTR2007-005389-11-GBniversity of Oxford10